{"id":188742,"date":"2024-05-06T00:22:25","date_gmt":"2024-05-06T05:22:25","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/05\/new-influenza-vaccine-strategies-aim-to-enhance-protection-with-t-cell-responses"},"modified":"2024-05-06T00:22:25","modified_gmt":"2024-05-06T05:22:25","slug":"new-influenza-vaccine-strategies-aim-to-enhance-protection-with-t-cell-responses","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/05\/new-influenza-vaccine-strategies-aim-to-enhance-protection-with-t-cell-responses","title":{"rendered":"New influenza vaccine strategies aim to enhance protection with T-cell responses"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-influenza-vaccine-strategies-aim-to-enhance-protection-with-t-cell-responses2.jpg\"><\/a><\/p>\n<p>In a recent review published in the journal <a href=\"https:\/\/www.nature.com\/articles\/s41577-024-01030-8\" rel=\"noopener\"><em>Nature Reviews Immunology<\/em><\/a><em>, <\/em>researchers discussed the limitations of current influenza vaccines and the potential for future vaccines to induce both T-cell responses and antibodies for enhanced protection. They examined the strategies to develop influenza vaccines with broad strain specificity and long-term <a href=\"https:\/\/www.news-medical.net\/health\/What-Does-Efficacy-Mean.aspx\" class=\"\">efficacy<\/a>, covering protection requirements, immune response evaluation, expected outcomes, and financial considerations.<\/p>\n<p>Study: Opportunities and challenges for T cell-based influenza vaccines. Image Credit: CI Photos \/ Shutterstock.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a recent review published in the journal Nature Reviews Immunology, researchers discussed the limitations of current influenza vaccines and the potential for future vaccines to induce both T-cell responses and antibodies for enhanced protection. They examined the strategies to develop influenza vaccines with broad strain specificity and long-term efficacy, covering protection requirements, immune response [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,45],"tags":[],"class_list":["post-188742","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-finance"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/188742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=188742"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/188742\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=188742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=188742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=188742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}